Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease
by
Raffaele KC, Asthana S, Berardi A,
Haxby JV, Morris PP, Schapiro MB, Soncrant TT.
Laboratory of Neurosciences,
National Institute on Aging,
National Institutes of Health,
Bethesda, MD, USA.
Neuropsychopharmacology 1996 Aug;15(2):163-70

ABSTRACT

Nine patients with possible or probable dementia of the Alzheimer type were tested on nine cognitive tests prior to (two times) and during continuous intravenous administration of five different doses of the muscarinic cholinergic agonist arecoline (1, 4, 16, 28, and 40 mg/day). The present analysis examined whether improvement on cognitive testing for each patient during arecoline treatment was most likely to occur at the same dose for all tests or whether different test scores improved at different doses of arecoline. Results indicated there were significant differences among tests in the dose at which most patients showed improved cognitive performance. These differences may have therapeutic significance, as verbal ability tended to improve at low doses of arecoline, whereas attention and visuospatial ability tended to improve at higher doses of arecoline.

Betel nut
Curcumin
Blueberries
Vinpocetine
Meclofenoxate
New brain cells
Centrophenoxine
The memory switch?
Dumb-drug euphoria
Growing new brain cells

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Utopian Pharmacology
SMART DRUGS 2: review
The Hedonistic Imperative
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family